H.R. 5547 118th Congress
Maintaining Investments in New Innovation Act
- Health
- Sponsor: Rep. Nickel, Wiley [D-NC-13]
- Congress.gov ↗
Latest action, Dec 17, 2024: Referred to the Subcommittee on Health.
How the Senate voted
The Senate hasn't taken a roll call on this bill in the Congresses covered.
28 cosponsors
Sponsored by Rep. Nickel, Wiley [D-NC-13] (Democrat). Cosponsors by party, House members included:
- Democrats
- Republicans
- Independents
Cosponsors
5 D · 23 R
Referred to: House: Energy and Commerce Committee; House: Ways and Means Committee
Who lobbied on it
Clients whose quarterly lobbying reports named it, each quarter.
The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.
ALNYLAM PHARMACEUTICALS
THE MCMANUS GROUP
6 reports
ALNYLAM PHARMACEUTICALS, INC.
TIBER CREEK GROUP
6 reports
ALNYLAM PHARMACEUTICALS, INC.
SPLITOAK STRATEGIES LLC
6 reports
GENENTECH
THE MCMANUS GROUP
5 reports
NOVARTIS
RESOLUTION PUBLIC AFFAIRS, LLC
5 reports
NOVARTIS
BROWNSTEIN HYATT FARBER SCHRECK, LLP
5 reports
NOVARTIS, INC.
FORBES-TATE
5 reports
4 reports
4 reports
NOVARTIS
TIBER CREEK HEALTH STRATEGIES, INC.
4 reports
NOVARTIS, INC.
TODD STRATEGY GROUP
4 reports
TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF NOVARTIS)
TIBER CREEK GROUP
4 reports
3 reports
ALEXION PHARMACEUTICALS, INC.
TODD STRATEGY GROUP
3 reports
All 25 of 32 clients
| Client | Lobbying firm | Reports | Reports totaling | From | To | Senate |
|---|---|---|---|---|---|---|
| ALNYLAM PHARMACEUTICALS | THE MCMANUS GROUP | 6 | $0 | Q4 2023 | Q3 2024 | yes |
| ALNYLAM PHARMACEUTICALS, INC. | TIBER CREEK GROUP | 6 | $0 | Q4 2023 | Q3 2024 | yes |
| ALNYLAM PHARMACEUTICALS, INC. | SPLITOAK STRATEGIES LLC | 6 | $0 | Q4 2023 | Q3 2024 | yes |
| GENENTECH | THE MCMANUS GROUP | 5 | $0 | Q4 2023 | Q3 2024 | yes |
| NOVARTIS | RESOLUTION PUBLIC AFFAIRS, LLC | 5 | $0 | Q4 2023 | Q3 2024 | yes |
| NOVARTIS | BROWNSTEIN HYATT FARBER SCHRECK, LLP | 5 | $0 | Q4 2023 | Q3 2024 | yes |
| NOVARTIS, INC. | FORBES-TATE | 5 | $0 | Q4 2023 | Q3 2024 | yes |
| AMGEN INC | 4 | $11.6M | Q1 2024 | Q3 2024 | yes | |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | 4 | $7.1M | Q4 2023 | Q3 2024 | yes | |
| NOVARTIS | 4 | $6.0M | Q1 2024 | Q3 2024 | yes | |
| NOVARTIS | TIBER CREEK HEALTH STRATEGIES, INC. | 4 | $0 | Q1 2024 | Q3 2024 | yes |
| NOVARTIS, INC. | TODD STRATEGY GROUP | 4 | $0 | Q1 2024 | Q3 2024 | yes |
| TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF NOVARTIS) | TIBER CREEK GROUP | 4 | $240K | Q1 2024 | Q3 2024 | yes |
| AARP | 3 | $14.4M | Q1 2024 | Q3 2024 | yes | |
| ALEXION PHARMACEUTICALS, INC. | TODD STRATEGY GROUP | 3 | $240K | Q4 2024 | Q3 2024 | yes |
| ALNYLAM PHARMACEUTICALS, INC. | TODD STRATEGY GROUP | 3 | $0 | Q4 2024 | Q3 2024 | yes |
| GILEAD SCIENCES, INC. | THE MCMANUS GROUP | 3 | $0 | Q4 2024 | Q3 2024 | yes |
| GSK (FKA GLAXOSMITHKLINE INC.) | 3 | $3.8M | Q4 2023 | Q2 2024 | yes | |
| HARMONY BIOSCIENCES | 3 | $450K | Q4 2024 | Q3 2024 | yes | |
| HEALTHCARE INSTITUTE OF NEW JERSEY | 3 | $159K | Q4 2024 | Q3 2024 | yes | |
| NOVARTIS | TARPLIN, DOWNS & YOUNG, LLC | 3 | $0 | Q4 2024 | Q3 2024 | yes |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 3 | $23.0M | Q4 2023 | Q2 2024 | yes | |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | THE MCMANUS GROUP | 3 | $0 | Q4 2024 | Q3 2024 | yes |
| ALNYLAM PHARMACEUTICALS, INC. | 2 | $440K | Q4 2023 | Q3 2023 | yes | |
| IONIS PHARMACEUTICAL, INC. | FORBES-TATE | 2 | $60K | Q4 2024 | Q3 2024 | yes |